F. Manapov

发表

ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer.

D. de Ruysscher, P. van Houtte, C. Faivre-Finn, 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Concomitant Trimodality Therapy of Re-irradiation, Chemotherapy and Regional Hyperthermia for a Pretreated Inoperable Sarcoma Recurrence

R. Issels, M. Niyazi, Minglun Li, 2015, Tumori.

Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer—A Prospective Longitudinal Assessment

Minglun Li, C. Eze, F. Manapov, 2021, Diagnostics.

Multimodal "synergistic" treatment based on tumour immunological contexture for advanced non-driver non-small cell lung cancer: A myth or reality?

C. Belka, C. Eze, O. Roengvoraphoj, 2020, European journal of cancer care.

Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

C. Belka, S. Reu, M. Orth, 2020, Radiation Oncology.

Stereotactic radiotherapy of intrapulmonary lesions: comparison of different dose calculation algorithms for Oncentra MasterPlan®

C. Belka, S. Gerum, M. Söhn, 2015, Radiation oncology.

Prophylactic cranial irradiation in small-cell lung cancer: update on patient selection, efficacy and outcomes

C. Belka, C. Eze, O. Roengvoraphoj, 2018, Lung Cancer.

Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer

C. Belka, C. Eze, O. Roengvoraphoj, 2020, Radiation oncology.

Revisiting the role of dose escalation in esophageal cancer in the era of modern radiation delivery

L. Sawicki, C. Eze, N. Schmidt-Hegemann, 2020, Journal of thoracic disease.

Prognostic factors for survival and radiation necrosis after stereotactic radiosurgery alone or in combination with whole brain radiation therapy for 1–3 cerebral metastases

C. Belka, M. Niyazi, L. Schüttrumpf, 2014, Radiation oncology.

PET/CT for Target Delineation of Lung Cancer Before Radiation Therapy.

M. Unterrainer, C. Eze, F. Manapov, 2022, Seminars in nuclear medicine.

Pooled analysis on image‐guided moderately hypofractionated thoracic irradiation in inoperable node‐positive/recurrent patients with non–small cell lung cancer with poor prognostic factors and severely limited pulmonary function and reserve

C. Belka, Minglun Li, S. Schönecker, 2022, Cancer.

Treatment Response and Prophylactic Cranial Irradiation Are Prognostic Factors in a Real‐life Limited‐disease Small‐cell Lung Cancer Patient Cohort Comprehensively Staged With Cranial Magnetic Resonance Imaging

C. Belka, G. Hildebrandt, R. Fietkau, 2017, Clinical lung cancer.

Primary tumor response to chemoradiotherapy in limited-disease small-cell lung cancer correlates with duration of brain-metastasis free survival

C. Belka, G. Hildebrandt, R. Fietkau, 2012, Journal of Neuro-Oncology.

Chemoradiotherapy of stage III small‐cell lung cancer: Can we further optimize multimodal treatment of N3 disease based on current evidence?

C. Eze, O. Roengvoraphoj, N. Schmidt-Hegemann, 2018, The clinical respiratory journal.

Optimization of curative-intended multimodal therapy in patientswith limited (UICC I-IIIA-C 8th Ed.) disease small cell lung cancerbased on the analysis of treatment-related factors

F. Manapov, 2018 .

Prognostic role of patient gender in limited-disease small-cell lung cancer treated with chemoradiotherapy

C. Belka, G. Hildebrandt, R. Fietkau, 2016, Strahlentherapie und Onkologie.

Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort

C. Belka, G. Hildebrandt, R. Fietkau, 2016, Journal of Cancer.

Timing of failure in limited disease (stage I-III) small-cell lung cancer patients treated with chemoradiotherapy: a retrospective analysis.

C. Belka, G. Hildebrandt, R. Fietkau, 2013, Tumori.

Timing of thoracic irradiation in limited stage small-cell lung cancer: is it still a star on the rise?

M. Niyazi, Minglun Li, F. Manapov, 2013, Radiation oncology journal.

Timing of Failure in Limited Disease (Stage I-III) Small-Cell Lung Cancer Patients Treated with Chemoradiotherapy: A Retrospective Analysis

C. Belka, G. Hildebrandt, R. Fietkau, 2013, Tumori.

Chemoradiotherapy duration correlates with overall survival in limited disease SCLC patients with poor initial performance status who successfully completed multimodality treatment

C. Belka, G. Hildebrandt, R. Fietkau, 2011, Strahlentherapie und Onkologie.

How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience

C. Belka, P. Bartenstein, R. Huber, 2018, European Journal of Nuclear Medicine and Molecular Imaging.

State of clinical research of radiotherapy/chemoradiotherapy and immune checkpoint inhibitor therapy combinations in solid tumours-a German radiation oncology survey.

C. Belka, M. Niyazi, C. Eze, 2019, European journal of cancer.

Clinical relevance of the M1b and M1c descriptors from the proposed TNM 8 classification of lung cancer

U. Müller-Lisse, R. Huber, K. Kahnert, 2017, Strahlentherapie und Onkologie.

Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations

S. Reu, R. Huber, K. Kahnert, 2020, Oncology Research and Treatment.

Maximum standardized uptake value of primary tumor (SUVmax_PT) and horizontal range between two most distant PET-positive lymph nodes predict patient outcome in inoperable stage III NSCLC patients after chemoradiotherapy.

C. Belka, Minglun Li, E. Mille, 2020, Translational lung cancer research.

Redefining the Role of Prophylactic Cranial Irradiation in the Modern Era of Active Surveillance in Small Cell Lung Cancer.

C. Eze, F. Manapov, L. Käsmann, 2019, JAMA oncology.

Stereoscopic X-ray imaging, cone beam CT, and couch positioning in stereotactic radiotherapy of intracranial tumors: preliminary results from a cross-modality pilot installation

C. Belka, M. Niyazi, U. Ganswindt, 2016, Radiation oncology.

Immune Checkpoint Inhibition Combined With Intracranial Stereotactic Radiation Therapy in Non-Small Cell Lung Cancer: Is There an Increasing Rate of Radionecrosis or Not? In Regards to Schapira et al, Huppeling et al and Colaco et al.

C. Eze, O. Roengvoraphoj, F. Manapov, 2018, International journal of radiation oncology, biology, physics.

Mediastinal lymph node clearance and anti-PD-1 induction in resected NSCLC.

C. Eze, O. Roengvoraphoj, F. Manapov, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Stereotactic Body Radiation Therapy (SBRT) Combined with Immune Check-Point Inhibition (ICI) in Advanced Lung Cancer: Which Metastatic Site Should Be Irradiated to Induce Immunogenic Cell Death?

C. Eze, F. Manapov, L. Käsmann, 2020, International journal of radiation oncology, biology, physics.

Combination of pembrolizumab with radiotherapy can change treatment paradigm in metastatic “non‐driver” non‐small‐cell lung cancer: Assembling a path

C. Eze, F. Manapov, J. Taugner, 2021, The clinical respiratory journal.

Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy—case report

M. Fischereder, F. Manapov, U. Grabmaier, 2021, Translational lung cancer research.

Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer

C. Belka, R. Huber, Minglun Li, 2017, Strahlentherapie und Onkologie.

Primary radiation therapy in stage I/II indolent orbital lymphoma – a comprehensive retrospective recurrence and toxicity analysis

C. Belka, Minglun Li, M. Dreyling, 2022, European journal of haematology.

of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent

C. Belka, S. Reu, M. Orth, 2019 .

Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis

N. Reinmuth, C. Belka, C. Eze, 2022, Journal of Cancer Research and Clinical Oncology.

Is cetuximab-induced rash conclusion really a remnant of the skin erythema dose?

C. Belka, F. Manapov, F. Oskan, 2013, International journal of radiation oncology, biology, physics.

Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab

C. Belka, C. Eze, F. Manapov, 2022, BMC Cancer.

Forging a Path for Metformin Use in Inoperable Locally Advanced Non-Small Cell Lung Cancer.

C. Belka, C. Eze, F. Manapov, 2021, JAMA oncology.

Feasibility of hypofractionated radiotherapy in inoperable node-positive NSCLC patients with poor prognostic factors and limited pulmonary reserve: a prospective observational study

C. Belka, Minglun Li, C. Eze, 2021, Acta oncologica.

Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol fo

N. Reinmuth, F. Klauschen, C. Belka, 2021, Translational lung cancer research.

Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy

C. Belka, C. Eze, O. Roengvoraphoj, 2020, Radiation oncology.

Chemo-/immuno-/radiotherapy combination in treatment of solid cancer

F. Manapov, J. Taugner, L. Käsmann, 2019, Oncotarget.

Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis

C. Belka, C. Eze, O. Roengvoraphoj, 2019, Radiation Oncology.

Pneumonitis in Irradiated Lungs After Nivolumab: A Brief Communication and Review of the Literature.

Minglun Li, C. Eze, S. Marschner, 2017, Journal of immunotherapy.

Daily Routine and Access to Care: Initial Patient Reported Experiences at a German Lung Cancer Center during the COVID-19 Pandemic

K. Kahnert, J. Behr, F. Manapov, 2020, Respiration.

Prophylactic Cranial Irradiation in Resected Small Cell Lung Cancer: Comprehensive Staging, Adjuvant Chemotherapy, and Strict Stratification of Pathological Stage Play a Role.

C. Eze, O. Roengvoraphoj, F. Manapov, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prophylactic Cranial Irradiation in Resected Early-Stage Small Cell Lung Cancer.

C. Eze, O. Roengvoraphoj, F. Manapov, 2017, International journal of radiation oncology, biology, physics.

Moderate hypofractionated image-guided thoracic radiotherapy for locally advanced node-positive non-small cell lung cancer patients with very limited lung function: a case report

Minglun Li, C. Eze, O. Roengvoraphoj, 2017, Radiation oncology journal.

Simultaneous bilateral stereotactic body radiation therapy of two inoperable centrally located pulmonary lesions in a patient with metastatic mesenchymal chondrosarcoma

C. Belka, U. Ganswindt, H. Ostermann, 2016 .

Why is survival after pembrolizumab affected by previous radiotherapy?

C. Eze, O. Roengvoraphoj, F. Manapov, 2017, The Lancet. Oncology.

Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature

C. Eze, O. Roengvoraphoj, F. Manapov, 2017, Front. Oncol..

Novel Multimodal Management of Post-Partum Synchronous Metastatic Pulmonary EBV-Associated Lymphoepithelioma-Like Carcinoma (LELC)—A Case Report

J. Neumann, T. Kirchner, M. Unterrainer, 2021, Diagnostics.

Radiation-induced lung toxicity – cellular and molecular mechanisms of pathogenesis, management, and literature review

B. Jeremic, D. de Ruysscher, S. Senan, 2020, Radiation oncology.

Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients

C. Belka, K. Unger, Minglun Li, 2021, Theranostics.

Changes in Behavior After Vaccination and Opinions Toward Mask Wearing: Thoracic Oncology Patient–Reported Experiences During the COVID-19 Pandemic

K. Kahnert, F. Manapov, A. Tufman, 2022, Clinical Medicine Insights. Oncology.

Radiation-induced lung toxicity – cellular and molecular mechanisms of pathogenesis, management, and literature review

B. Jeremic, D. de Ruysscher, S. Senan, 2020, Radiation Oncology.

Mature results of a randomized trial comparing two fractionation schedules of high dose rate endoluminal brachytherapy for the treatment of endobronchial tumors

C. Belka, S. Corradini, R. Huber, 2013, Radiation Oncology.

Role of Postoperative Radiotherapy in the Management for Resected NSCLC - Decision Criteria in Clinical Routine Pre- and Post-LungART.

D. de Ruysscher, R. Dziadziuszko, P. van Houtte, 2021, Clinical Lung Cancer.

Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition

N. Reinmuth, C. Belka, Minglun Li, 2021, European Journal of Nuclear Medicine and Molecular Imaging.

PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions

C. Belka, J. Dinkel, L. Sawicki, 2021, European Journal of Nuclear Medicine and Molecular Imaging.

Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis

L. Heinzerling, C. Belka, S. Corradini, 2023, Clinical and translational radiation oncology.

Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports

C. Belka, C. Eze, F. Manapov, 2023, Expert opinion on investigational drugs.

Finger Pain as an Uncommon Primary Manifestation of Lung Carcinoma

H. Dürr, M. Unterrainer, A. Stäbler, 2023, Diagnostics.

Evaluation of the role of remission status in a heterogeneous limited disease small-cell lung cancer patient cohort treated with definitive chemoradiotherapy

Claus Belka, Maximilian Niyazi, Minglun Li, 2016, BMC Cancer.

Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease

M. Wildgruber, S. Corradini, M. Niyazi, 2021, Frontiers in Oncology.

Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy.

C. Belka, C. Eze, O. Roengvoraphoj, 2019, Translational lung cancer research.

Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition

N. Reinmuth, C. Belka, Minglun Li, 2021, Investigational New Drugs.

Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting

N. Reinmuth, C. Belka, C. Eze, 2021, Cancers.

Association of Planning Target Volume with Patient Outcome in Inoperable Stage III NSCLC Treated with Chemoradiotherapy: A Comprehensive Single-Center Analysis

C. Belka, C. Eze, O. Roengvoraphoj, 2020, Cancers.

Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey

C. Belka, C. Eze, O. Roengvoraphoj, 2020, Translational lung cancer research.

Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy

C. Belka, C. Eze, O. Roengvoraphoj, 2020, AntiCancer Research.

Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest.

C. Eze, F. Manapov, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Stereotactic radiotherapy of intrapulmonary lesions: comparison of different dose calculation algorithms for Oncentra MasterPlan®

C. Belka, S. Gerum, M. Söhn, 2015, Radiation oncology.

Towards homogenization of total body irradiation practices in pediatric patients across SIOPE affiliated centers a survey by the SIOPE radiation oncology working group.

B. Hoeben, T. Boterberg, G. Janssens, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Prophylactic cranial irradiation in small-cell lung cancer.

C. Eze, F. Manapov, 2017, The Lancet. Oncology.

Timing of tumor-induced atelectasis resolution and pulmonary function restoration in the course of image-guided moderate hypofractionated thoracic irradiation: a case report and mini-review of literature

C. Belka, C. Eze, F. Manapov, 2021, BJR case reports.

Hypofractionated radiotherapy for prostate cancer

C. Belka, Minglun Li, M. Guckenberger, 2014, Radiation Oncology.

Preoperative Hilar and Mediastinal Lymph Node Staging in Patients with Suspected or Diagnosed Lung Cancer: Accuracy of 18F-FDG-PET/CT:A Retrospective Cohort Study of 138 Patients

P. Hohenberger, R. Hatz, F. Manapov, 2023, Diagnostics.

Prophylactic Cranial Irradiation for Patients with Small Cell Lung Cancer in Germany: Pattern of Care Survey

C. Belka, C. Eze, O. Roengvoraphoj, 2018, AntiCancer Research.

Prognostic Role of Lung Immune Scores for Prediction of Survival in Limited-stage Small Cell Lung Cancer

C. Eze, F. Manapov, J. Taugner, 2021, In Vivo.

External Validation of a Survival Score for Limited-Stage Small Cell Lung Cancer Patients Treated with Chemoradiotherapy

C. Belka, D. Rades, C. Eze, 2020, Lung.

Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment

C. Belka, C. Eze, O. Roengvoraphoj, 2019, AntiCancer Research.

Consequences of the COVID-19 pandemic on lung cancer care and patient health in a German lung cancer center: results from a cross-sectional questionnaire

K. Kahnert, F. Manapov, A. Tufman, 2022, Respiratory Research.

Automated biological target volume delineation for radiotherapy treatment planning using FDG-PET/CT

C. Belka, M. Niyazi, U. Ganswindt, 2013, Radiation oncology.

Automated biological target volume delineation for radiotherapy treatment planning using FDG-PET/CT

Claus Belka, Maximilian Niyazi, Marcus Hacker, 2013, Radiation Oncology.

Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment

N. Reinmuth, C. Belka, Minglun Li, 2023, European Journal of Nuclear Medicine and Molecular Imaging.

In regards to Chu et al.: Patterns of brain metastasis immediately before prophylactic cranial irradiation (PCI): implications for PCI optimization in limited-stage small cell lung cancer

C. Eze, F. Manapov, J. Taugner, 2020, Radiation oncology.

ESTRO ACROP guidelines for Target Volume Definition in the thoracic radiation treatment of Small cell lung cancer.

D. de Ruysscher, P. van Houtte, C. Faivre-Finn, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

MR-guided radiotherapy in node-positive non-small cell lung cancer and severely limited pulmonary reserve: a report proposing a new clinical pathway for the management of high-risk patients

C. Belka, S. Corradini, M. Niyazi, 2022, Radiation oncology.

Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients

R. Savai, T. Muley, R. Majeed, 2023, Cancer medicine.

Intrathoracic migration of a breast implant seven years after thoracotomy. A case report

M. Lindner, R. Hatz, F. Manapov, 2022, International journal of surgery case reports.

Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study

N. Reinmuth, C. Belka, C. Eze, 2023, Journal of Cancer Research and Clinical Oncology.

Comparison of prostate positioning guided by three-dimensional transperineal ultrasound and cone beam CT

C. Belka, S. Corradini, Minglun Li, 2016, Strahlentherapie und Onkologie.

A comparative assessment of prostate positioning guided by three-dimensional ultrasound and cone beam CT

C. Belka, Minglun Li, M. Reiner, 2015, Radiation Oncology.

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients

N. Reinmuth, C. Belka, C. Eze, 2021, Investigational New Drugs.

Central nervous system relapse continues to be a therapeutic challenge in extensive disease small-cell lung cancer patients with initial symptomatic brain metastases and good response to chemoradiotherapy

F. Manapov, 2010, Journal of Neuro-Oncology.

Stereoscopic X-ray imaging, cone beam CT, and couch positioning in stereotactic radiotherapy of intracranial tumors: preliminary results from a cross-modality pilot installation

C. Belka, M. Niyazi, U. Ganswindt, 2016, Radiation oncology.

A comparative assessment of prostate positioning guided by three-dimensional ultrasound and cone beam CT

C. Belka, Minglun Li, M. Reiner, 2015, Radiation oncology.

Positron Emission Tomography/Computed Tomography (PET/CT)-Based, Local Consolidative Radiotherapy after Chemoimmunotherapy in Metastatic, Non-Oncogene-Addicted Non-Small-Cell Lung Cancer (NSCLC)

F. Manapov, M. Pazos, L. Käsmann, 2023, Diagnostics.

Mature results of a randomized trial comparing two fractionation schedules of high dose rate endoluminal brachytherapy for the treatment of endobronchial tumors

C. Belka, S. Corradini, R. Huber, 2013, Radiation oncology.

Adjuvant radiotherapy additionally to chemotherapy in resected node‐positive small cell lung cancer: A role assessment without randomized evidence

C. Eze, O. Roengvoraphoj, F. Manapov, 2020, The clinical respiratory journal.

Histology of the Primary Tumor Correlates with False Positivity of Integrated 18F-FDG-PET/CT Lymph Node Staging in Resectable Lung Cancer Patients

P. Hohenberger, R. Hatz, F. Manapov, 2023, Diagnostics.

Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab

C. Belka, C. Eze, F. Manapov, 2022, BMC Cancer.

Evaluation of the role of remission status in a heterogeneous limited disease small-cell lung cancer patient cohort treated with definitive chemoradiotherapy

C. Belka, G. Hildebrandt, R. Fietkau, 2016, BMC Cancer.

68PD CHEMORADIOTHERAPY DURATION CORRELATES WITH OVERALL SURVIVAL IN LIMITED-DISEASE SMALL-CELL LUNG CANCER PATIENTS WITH POOR INITIAL PERFORMANCE STATUS WHO SUCCESSFULLY COMPLETED MULTIMODALITY TREATMENT

C. Belka, G. Hildebrandt, R. Fietkau, 2011 .

Prefraction displacement and intrafraction drift of the prostate due to perineal ultrasound probe pressure

Claus Belka, Minglun Li, Ute Ganswindt, 2017, Strahlentherapie und Onkologie.

Radiation-Induced Lung Injury: Prevention, Diagnostics and Therapy in the Era of the COVID-19 Pandemic

C. Belka, C. Eze, F. Manapov, 2022, Journal of clinical medicine.

Is it time to convert the frequency of radiotherapy in small-cell lung cancer?

C. Eze, O. Roengvoraphoj, F. Manapov, 2017, The Lancet Oncology.

18FDG-PET/CT for the Visualization of Inflammatory Component of Radiation-Induced Lung Injury After Stereotactic Radiotherapy.

C. Eze, O. Roengvoraphoj, F. Manapov, 2017, Clinical nuclear medicine.

N. Reinmuth, C. Belka, C. Eze, 2022, Journal of Cancer Research and Clinical Oncology.

Guideline adherence of tumor board recommendations in lung cancer and transfer into clinical practice

J. Dinkel, R. Huber, J. Neumann, 2023, Journal of Cancer Research and Clinical Oncology.

Dose-volumetric parameters and prediction of severe acute esophagitis in patients with locally-advanced non small-cell lung cancer treated with neoadjuvant concurrent hyperfractionated-accelerated chemoradiotherapy

C. Belka, M. Niyazi, W. Budach, 2013, Radiation oncology.

The role of online MR-guided multi-fraction stereotactic ablative radiotherapy in lung tumours

S. Corradini, M. Niyazi, C. Eze, 2024, Clinical and translational radiation oncology.

NICOLAS, DETERRED and KEYNOTE 799: focus on escalation of conventionally fractionated chemoradiotherapy by immune checkpoint inhibition in unresectable stage III non-small cell lung cancer

F. Manapov, L. Käsmann, S. Kenndoff, 2021, Translational lung cancer research.

First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis

C. Eze, F. Manapov, A. Tufman, 2023, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

Role of radiotherapy in the management of brain metastases of NSCLC - Decision criteria in clinical routine.

D. de Ruysscher, R. Dziadziuszko, P. van Houtte, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT).

K. Ulm, R. Fietkau, R. Huber, 2021, Lung cancer.